- The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα…
March 15, 2025 11:25 ET | Source: ZENTALIS PHARMACEUTICALS Azenosertib median duration of response (mDOR) updated to 6.3 months in…
NEW YORK and LONDON and MUNICH and NEW DELHI, Feb. 11, 2025 /PRNewswire/ -- Datar Cancer Genetics (DCG), a global leader…
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we,…
MUMBAI, India, Feb. 5, 2025 /PRNewswire/ -- On the occasion of World Cancer Day, the Centre for Environmental Research and Education…
The National Comprehensive Cancer Network joins a global day of advocacy to put people's individual needs and stories at the…
Cancer cases in India will see a 57.7% increase by 2040, unless a tailored policy is developed. NEW DELHI, Feb.…
LONDON, MUNICH and NEW DELHI, Feb. 3, 2025 /PRNewswire/ -- Datar Cancer Genetics (DCG) has launched Exacta AI, a next generation…
As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered…
NEW DELHI and LONDON and MUNICH, Jan. 28, 2025 /PRNewswire/ -- Datar Cancer Genetics (DCG) has launched a revolutionary video-reporting…
